MX2009002492A - Agentes que comprenden compuestos marcados con 18f y metodos relacionados. - Google Patents

Agentes que comprenden compuestos marcados con 18f y metodos relacionados.

Info

Publication number
MX2009002492A
MX2009002492A MX2009002492A MX2009002492A MX2009002492A MX 2009002492 A MX2009002492 A MX 2009002492A MX 2009002492 A MX2009002492 A MX 2009002492A MX 2009002492 A MX2009002492 A MX 2009002492A MX 2009002492 A MX2009002492 A MX 2009002492A
Authority
MX
Mexico
Prior art keywords
compounds
methods
labeled agents
labeled
agents
Prior art date
Application number
MX2009002492A
Other languages
English (en)
Spanish (es)
Inventor
Keith Graham
Thomas Brumby
Lutz Lehmann
Ananth Srinivasan
Detlev Suelzle
Timo Stellfeld
Mylene Karramkam
Simon Ametamey
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2009002492A publication Critical patent/MX2009002492A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2009002492A 2006-09-08 2007-09-07 Agentes que comprenden compuestos marcados con 18f y metodos relacionados. MX2009002492A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules
PCT/EP2007/008042 WO2008028688A2 (en) 2006-09-08 2007-09-07 Compounds and methods for 18f labeled agents

Publications (1)

Publication Number Publication Date
MX2009002492A true MX2009002492A (es) 2009-08-28

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002492A MX2009002492A (es) 2006-09-08 2007-09-07 Agentes que comprenden compuestos marcados con 18f y metodos relacionados.

Country Status (20)

Country Link
US (1) US8557776B2 (OSRAM)
EP (5) EP3056509A1 (OSRAM)
JP (2) JP5603074B2 (OSRAM)
KR (1) KR20090058553A (OSRAM)
AR (1) AR062726A1 (OSRAM)
AU (1) AU2007294124A1 (OSRAM)
BR (1) BRPI0716554A2 (OSRAM)
CA (2) CA2858907A1 (OSRAM)
CL (1) CL2007002620A1 (OSRAM)
CO (1) CO6150196A2 (OSRAM)
CR (1) CR10654A (OSRAM)
IL (4) IL197363A0 (OSRAM)
MA (1) MA30780B1 (OSRAM)
MX (1) MX2009002492A (OSRAM)
NO (1) NO20091428L (OSRAM)
PE (1) PE20080850A1 (OSRAM)
RU (1) RU2009112716A (OSRAM)
TN (1) TN2009000063A1 (OSRAM)
TW (1) TW200829277A (OSRAM)
WO (1) WO2008028688A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557776B2 (en) 2006-09-08 2013-10-15 Bayer Pharma AG Compounds and methods for 18F labeled agents
US20090317326A1 (en) * 2007-03-01 2009-12-24 Ananth Srinivasan Radiofluorination methods
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
JP2014526952A (ja) * 2011-06-09 2014-10-09 ジーイー・ヘルスケア・リミテッド 蒸留装置及び方法
ES2743433T3 (es) * 2013-03-15 2020-02-19 Cancer Targeted Tech Llc Agentes para imágenes de pet dirigidos a psma marcados con 18F
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US11518754B2 (en) 2017-02-17 2022-12-06 Yale University Radiolabeled pharmaceuticals and methods of making and using same
IL271903B2 (en) 2017-07-11 2025-04-01 Synthorx Inc Combination of unnatural nucleotides and methods therefor
SG11202000939PA (en) 2017-08-03 2020-02-27 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
US20210238124A1 (en) * 2018-04-20 2021-08-05 The General Hospital Corporation Acetylated prodrugs for delivery across the blood-brain barrier
EP3923974A4 (en) 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
WO2022246118A2 (en) * 2021-05-20 2022-11-24 The Regents Of The University Of California Pet imaging tracers
KR20250164815A (ko) 2023-03-31 2025-11-25 닛산 가가쿠 가부시키가이샤 피라졸 화합물 및 유해 생물 방제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
JP2795449B2 (ja) * 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
DE68928667T2 (de) * 1988-10-14 1998-10-01 Univ Tulane Peptide als arzneimittel
JP2846463B2 (ja) * 1989-06-02 1999-01-13 ジョージタウン・ユニバーシティー 抗ストレプトキナーゼ抗体の検出方法
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
ID25551A (id) 1997-12-24 2000-10-12 Vertex Pharma Bahan baku obat penghambat protease aspartil
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
WO2002044144A2 (en) * 2000-11-30 2002-06-06 Advanced Research And Technology Institute, Inc. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
ATE332307T1 (de) 2002-04-09 2006-07-15 Lilly Co Eli Wachstumhormonsekretionsförderer
AU2003250899A1 (en) * 2002-08-09 2004-03-11 Astellas Pharma Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
EP1597270A2 (en) 2003-02-20 2005-11-23 University of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
CN101583352A (zh) 2005-07-29 2009-11-18 拜尔健康护理有限责任公司 治疗肥胖症的联苯氨基酸衍生物的制备和用途
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
US8557776B2 (en) 2006-09-08 2013-10-15 Bayer Pharma AG Compounds and methods for 18F labeled agents

Also Published As

Publication number Publication date
CR10654A (es) 2009-04-14
EP2063918B1 (en) 2014-02-26
JP2010503618A (ja) 2010-02-04
WO2008028688A3 (en) 2008-11-13
EP2279759A3 (en) 2013-04-17
WO2008028688A2 (en) 2008-03-13
EP3056509A1 (en) 2016-08-17
CA2662449A1 (en) 2008-03-13
RU2009112716A (ru) 2010-10-20
NO20091428L (no) 2009-06-03
IL211527A0 (en) 2011-05-31
IL211526A0 (en) 2011-05-31
BRPI0716554A2 (pt) 2013-09-24
PE20080850A1 (es) 2008-09-02
EP2289564A3 (en) 2012-11-14
EP2289564A2 (en) 2011-03-02
IL211033A0 (en) 2011-04-28
JP5603074B2 (ja) 2014-10-08
KR20090058553A (ko) 2009-06-09
TN2009000063A1 (en) 2010-08-19
TW200829277A (en) 2008-07-16
JP5722966B2 (ja) 2015-05-27
AR062726A1 (es) 2008-11-26
CL2007002620A1 (es) 2008-05-30
IL197363A0 (en) 2011-08-01
AU2007294124A1 (en) 2008-03-13
CA2858907A1 (en) 2008-03-13
CO6150196A2 (es) 2010-04-20
EP2063918A2 (en) 2009-06-03
MA30780B1 (fr) 2009-10-01
US20080292548A1 (en) 2008-11-27
EP2455105B1 (en) 2016-02-17
EP2279759A2 (en) 2011-02-02
EP2455105A3 (en) 2012-09-05
US8557776B2 (en) 2013-10-15
JP2014028813A (ja) 2014-02-13
EP2455105A2 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
TN2009000063A1 (en) Compounds and methods for 18f labeled agents
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
BRPI0908926A2 (pt) Compostos de policarbonato-poliorganosiloxano e/ou poliuretano-poliorganosiloxano
ZA200702700B (en) Diagnostic compounds
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
MX2009004435A (es) Tinturas dispersas, su preparacion y su uso.
MX2010004493A (es) Compuestos de tropano.
WO2009024342A3 (en) Novel microbiocides
TN2010000064A1 (en) Novel herbicides
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
MX2011007998A (es) Nuevos herbicidas.
TNSN07383A1 (en) 1-h-quinazoline-2,4-diones and their use as ampa-receptor ligands
MY161132A (en) Novel herbicides
MX2010001364A (es) Derivados de ciclopentandiona puenteados triciclicos como herbicidas.
MX2011007932A (es) Herbicidas nuevos.
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
IL200469A0 (en) Benzimidazole derivatives
TN2011000355A1 (en) Novel microbiocides
WO2009127718A3 (en) Novel microbiocides
MX2009012471A (es) Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6.
TN2009000100A1 (en) Silicon derivatives for pet imaging
TW200940659A (en) Azopyridone disperse dyes, their preparation and use
WO2009003672A3 (en) Novel microbiocides
WO2009035959A3 (en) Radiofluorination methods
TN2010000094A1 (en) Novel herbicides

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal